Status | Study |
Recruiting |
Study Name: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid Condition: Pemphigoid, Bullous Date: 2014-07-27 Interventions: Biological: Bertilimumab |
Completed |
Study Name: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Condition: Pemphigoid, Bullous Date: 2012-10-05 Interventions: Drug: Mepolizumab (a-IL-5 antibody) |
Terminated |
Study Name: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment Condition: Bullous Pemphigoid Date: 2012-09-17 Interventions: Drug: QGE031 QGE031 will be ev |
Terminated |
Study Name: Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2012-04-04 Interventions: Drug: DF2156A DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand |
Recruiting |
Study Name: Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Condition: Pemphigoid, Bullous Pemphigus Date: 2012-03-19 |
Completed |
Study Name: Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Condition: Bullous Pemphigoid Date: 2011-07-27 Interventions: Drug: NPB-01 Intravenous immun |
Recruiting |
Study Name: Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Condition: Bullous Pemphigoid Pruritus Date: 2010-12-21 |
Completed |
Study Name: Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Condition: Bullous Pemphigoid Date: 2008-12-11 Interventions: Drug: NPB-01 Intravenous immun |
Completed |
Study Name: Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2008-12-03 Interventions: Drug: leflunomide |
Completed |
Study Name: Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Condition: Ocular Cicatricial Pemphigoid Date: 2007-12-26 Interventions: Drug: Rituximab The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses ( |